Quality of Life Study With Adalimumab in Rheumatoid Arthritis

Study Identifier
MEXI -P01-03
CT.gov Identifier
NCT00234936
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
  • Adalimumab
  • Methotrexate
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history - Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria - Subjects with treatment failure criteria to Mtx or Mtx + another DMARD
    Exclusion Criteria:
    - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Female subject who is pregnant or breast-feeding or considering becoming pregnant - Previous treatment with approved biological agents (etanercept, infliximab, anakinra) in the last 2 months

    Protocol Summary

    The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate

    to improve the quality of life in patients with active RA.

    Study Locations

    No locations found.